[go: up one dir, main page]

ECSP088824A - Prolinamidas sustituidas, su preparación y su uso como medicamentos - Google Patents

Prolinamidas sustituidas, su preparación y su uso como medicamentos

Info

Publication number
ECSP088824A
ECSP088824A EC2008008824A ECSP088824A ECSP088824A EC SP088824 A ECSP088824 A EC SP088824A EC 2008008824 A EC2008008824 A EC 2008008824A EC SP088824 A ECSP088824 A EC SP088824A EC SP088824 A ECSP088824 A EC SP088824A
Authority
EC
Ecuador
Prior art keywords
medicines
preparation
prolinamides
substituted
substituted prolinamides
Prior art date
Application number
EC2008008824A
Other languages
English (en)
Inventor
Kai Gerlach
Roland Pfau
Henning Priepke
Wolfgang Wienen
Annette Maria Schuler-Metz
Georg Dahmann
Herbert Nar
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP088824A publication Critical patent/ECSP088824A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Son objeto de la presente invención nuevas prolinamidas sustituidas de la fórmula general (I) (I)en donde D, L, E, G, J, M, R3, R4, R5 y R13 se definen como en la descripción, sus tautómeros, sus enantiómeros, sus diastereómeros, sus mezclas y sus sales, en especial sus sales fisiológicamente tolerables con ácidos o bases inorgánicos u orgánicos, que presentan valiosas propiedades.
EC2008008824A 2006-05-16 2008-10-15 Prolinamidas sustituidas, su preparación y su uso como medicamentos ECSP088824A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06113977 2006-05-16
EP07102566 2007-02-16

Publications (1)

Publication Number Publication Date
ECSP088824A true ECSP088824A (es) 2008-11-27

Family

ID=38646563

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008824A ECSP088824A (es) 2006-05-16 2008-10-15 Prolinamidas sustituidas, su preparación y su uso como medicamentos

Country Status (23)

Country Link
US (1) US7807693B2 (es)
EP (1) EP2051975B1 (es)
JP (1) JP5263686B2 (es)
KR (1) KR101422456B1 (es)
AR (1) AR060945A1 (es)
AU (1) AU2007251614B2 (es)
BR (1) BRPI0711648A2 (es)
CA (1) CA2653753C (es)
CL (1) CL2007001391A1 (es)
DK (1) DK2051975T3 (es)
EA (1) EA200802210A1 (es)
EC (1) ECSP088824A (es)
ES (1) ES2395538T3 (es)
IL (1) IL195245A (es)
MX (1) MX2008014499A (es)
MY (1) MY146623A (es)
NO (1) NO20084530L (es)
NZ (1) NZ573573A (es)
PE (1) PE20080702A1 (es)
PL (1) PL2051975T3 (es)
TW (1) TW200813047A (es)
UY (1) UY30352A1 (es)
WO (1) WO2007131982A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
JP5524852B2 (ja) 2007-11-15 2014-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換アミド、それらの製造及び医薬品としての使用
CN102046624A (zh) * 2008-03-31 2011-05-04 埃沃特克股份有限公司 作为组胺h3受体拮抗剂的四氢萘啶及其氮杂衍生物
GB201209138D0 (en) * 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
WO2014127815A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones i
JP6337750B2 (ja) * 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
JP6466461B2 (ja) 2014-02-03 2019-02-06 ヴァイティー ファーマシューティカルズ，インコーポレイテッド Ｒｏｒガンマのジヒドロピロロピリジン阻害剤
LT3828173T (lt) * 2014-03-07 2022-11-10 Biocryst Pharmaceuticals, Inc. Pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
EP3207043B3 (en) 2014-10-14 2019-10-02 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
JP6914257B2 (ja) 2015-11-20 2021-08-04 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのモジュレーター
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2019023207A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. Inhibitors of rorϒ
CN114646701B (zh) * 2022-03-01 2023-09-29 浙江国邦药业有限公司 一种l-脯氨酰胺中有关物质的hplc测试方法
AU2024250528A1 (en) * 2023-04-14 2025-10-23 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP3975254B2 (ja) * 2002-07-25 2007-09-12 日野自動車株式会社 チャイルドシート用アンカの取付構造
NZ543366A (en) * 2003-04-03 2008-11-28 Merck Patent Gmbh Carbonyl compounds
DE10329457A1 (de) 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate
DE502004001289D1 (de) 2003-06-18 2006-10-05 Merck Patent Gmbh PYRROLIDIN-1,2-DICARBONSÄURE-1-i(4-ETHINYL-PHENYL)-AMIDö-2-i(PHENYL)-AMIDö DERIVATE ALS INHIBITOREN DER KOAGULATIONSFAKTOREN XA UND VIIA ZUR BEHANDLUNG VON THROMBOSEN
ES2223277B1 (es) 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
DE10358814A1 (de) 2003-12-16 2005-07-21 Merck Patent Gmbh Prolinylarylacetamide
DE102004014945A1 (de) 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
US7453002B2 (en) * 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
WO2006108709A1 (en) 2005-04-11 2006-10-19 Glaxo Group Limited 3-sulfonylamino-pyrrolidine-2-one derivatives as factor xa inhibitors
AU2006271781A1 (en) * 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines

Also Published As

Publication number Publication date
EA200802210A1 (ru) 2009-06-30
US20080139605A1 (en) 2008-06-12
AR060945A1 (es) 2008-07-23
IL195245A (en) 2012-09-24
NZ573573A (en) 2011-10-28
UY30352A1 (es) 2008-01-02
AU2007251614A1 (en) 2007-11-22
HK1131140A1 (en) 2010-01-15
US7807693B2 (en) 2010-10-05
WO2007131982A2 (de) 2007-11-22
PE20080702A1 (es) 2008-07-10
TW200813047A (en) 2008-03-16
MX2008014499A (es) 2008-11-27
DK2051975T3 (da) 2012-10-15
JP5263686B2 (ja) 2013-08-14
MY146623A (en) 2012-09-14
NO20084530L (no) 2008-12-12
CA2653753C (en) 2013-09-24
JP2009537483A (ja) 2009-10-29
WO2007131982A3 (de) 2008-01-10
EP2051975B1 (de) 2012-09-12
KR20090017523A (ko) 2009-02-18
PL2051975T3 (pl) 2013-01-31
CL2007001391A1 (es) 2008-01-18
EP2051975A2 (de) 2009-04-29
KR101422456B1 (ko) 2014-07-23
AU2007251614B2 (en) 2013-01-17
CA2653753A1 (en) 2007-11-22
ES2395538T3 (es) 2013-02-13
BRPI0711648A2 (pt) 2011-11-29
IL195245A0 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
ECSP088824A (es) Prolinamidas sustituidas, su preparación y su uso como medicamentos
UY30979A1 (es) Pirrolidinamidas sustituidas, su preparacion y su uso como medicamentos
ECSP078058A (es) Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos
UY32463A (es) Derivados de (1-{[5-(4-halo-2-trifluorometil-fenilamino)piridin-2-ilmetil]-carbamoil -ciclopropil)-amidas de ácidos pirimidin-carboxílicos y similares; sus enantiómeros, sus diastereoisómeros, y sus sales, fisiológicamente tolerables.
UY28773A1 (es) Nuevas amidas de ácidos carboxílicos, su preparación y su uso como medicamentos.
ECSP109978A (es) Nuevos compuestos
ECSP066898A (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
CR11861A (es) Compuestos organicos
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
CO6390082A2 (es) Compuestos organicos
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteína quinasa activados por amp (ampk)
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP10010688A (es) Activadores de glucoquinasa
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
ECSP10010105A (es) Antagonistas de cgrp
UY31736A (es) Derivados sustituidos de pirazol y su uso
ECSP088194A (es) Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
DE602007008691D1 (de) Cyclische sulfone, die zur verwendung als bace-inhibitoren geeignet sind
UY31286A1 (es) Antagonistas de receptores de bradiquinina b1. proceso de preparación y aplicaciones.
CO6300943A2 (es) Derivados de 2-oxo-aquil-1-piperazin-2-ona su preparacion y su aplicacion en terapeutica
UY33092A (es) Compuestos de triazol, su uso y agentes que los contienen
AR108389A2 (es) Derivados de ácido fenilacético
UY29628A1 (es) Nuevas glicinamidas sustituidas, su preparación y su uso como medicamentos
CO6561812A2 (es) Derivados de 2-aldoximino-5-fluoropirimidina